Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alvotech

7.90
+0.03000.38%
Post-market: 8.020.1200+1.52%18:47 EDT
Volume:441.38K
Turnover:3.49M
Market Cap:2.46B
PE:36.32
High:8.01
Open:7.82
Low:7.79
Close:7.87
52wk High:13.70
52wk Low:7.35
Shares:311.60M
Float Shares:116.17M
Volume Ratio:1.20
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2175
EPS(LYR):-0.8654
ROE:--
ROA:2.83%
PB:-14.20
PE(LYR):-9.13

Loading ...

Alvotech Announces Key Leadership Changes in Commercial Operations

TIPRANKS
·
Oct 22

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

THOMSON REUTERS
·
Oct 22

Alvotech: Cco Anil Okay Stepping Down to Serve as CEO of Adalvo

THOMSON REUTERS
·
Oct 22

Alvotech Announces Leadership Changes in Global Commercial Team

Reuters
·
Oct 22

Alvotech Shares Rise After Morgan Stanley Upgrade

MT Newswires Live
·
Oct 15

Alvotech Raised to Overweight From Equal-Weight by Morgan Stanley

Dow Jones
·
Oct 14

Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14

MT Newswires Live
·
Oct 14

BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018

Reuters
·
Oct 06

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for Adl-018, a Proposed Biosimilar to Xolair® (Omalizumab)

THOMSON REUTERS
·
Oct 06

Alvotech, Advanz Pharma Say Europe Accepts Marketing Application for Asthma Drug Biosimilar

MT Newswires Live
·
Oct 06

Alvotech and Advanz Pharma’s Biosimilar to Xolair® (omalizumab), AVT23, Accepted for Regulatory Review by European Medicines Agency

Reuters
·
Oct 06

European Marketing Application for Avt23, a Proposed Biosimilar to Xolair® (Omalizumab), Accepted by the European Medicines Agency

THOMSON REUTERS
·
Oct 06

Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says

MT Newswires Live
·
Sep 23

Alvotech rises 12.9%

TIPRANKS
·
Sep 23

Alvotech Raised to Buy From Hold by Deutsche Bank

Dow Jones
·
Sep 23

Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14

MT Newswires Live
·
Sep 23

Alvotech upgraded to Buy from Hold at Deutsche Bank

TIPRANKS
·
Sep 23

Alvotech Sa : Deutsche Bank Raises to Buy From Hold

THOMSON REUTERS
·
Sep 23

Alvotech Gains Key Approvals for Biosimilars in Japan and Europe

TIPRANKS
·
Sep 23

European Medicines Agency Recommends Marketing Authorization of Avt03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

THOMSON REUTERS
·
Sep 22